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Intravesical (local) therapy of agents has been effective in delaying or preventing recurrence of superﬁcial
bladder cancer. This route of drug administration has also shown tremendous promise in the treatment
of interstitial cystitis/painful bladder syndrome (IC/PBS) and overactive bladder without systemic side
effects. Liposomes are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core.
They can incorporate drug molecules, both hydrophilic and hydrophobic, and show greater uptake into
cells via endocytosis. Intravesical liposomes have therapeutic effects on IC/PBS patients, mainly because
of their ability to form a protective lipid ﬁlm on the urothelial surface. Recent studies have shown the
sustained efﬁcacy and safety of intravesical instillation of botulinum toxin formulated with liposomes
(lipo-BoNT) for the treatment of refractory overactive bladder This review considers the current status of
intravesical liposomes or liposomal mediated drug delivery for the treatment of IC/PBS and overactive
bladder.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Intravesical therapy/drug delivery is widely used for delaying or
preventing the recurrence of superﬁcial bladder cancer.1 Intravesical
therapies with drug instillation in the bladder provides a high
concentration of drugs in the diseased bladder without an increase
in systemic levels and has low risk of systemic side effects.2 The
method of intravesical drug instillation is so popular in the ﬁeld of
urology, it would be wise to apply the lessons learned from treating
bladder cancer to improve the treatment of overactive bladder
(OAB) or interstitial cystitis/painful bladder syndrome (IC/PBS).
However, the impermeability of urothelial cells, a short duration of
action for many therapeutic agents, and the need for frequent
administration limited the applicability of intravesical therapy.2,3
Liposomes (LPs) are lipid vesicles composed of phospholipid
bilayers surrounding an aqueous core.4 Empty LPs can protect atment of Surgery, Kaohsiung
ty College of Medicine, 83301
.
huang).
ciation. Published by Elsevier Taiwwounded urothelium and have shown therapeutic beneﬁts for
IC/PBS patients.5 LPs can carry drugs to penetrate the urothelium
and modulate urothelial or suburothelial neurotransmission;
therefore, LPs might mitigate the symptoms of OAB or IC/PBS with
or without drug delivery.2,6 This review considers the current status
of intravesical LPs or liposomal mediated drug delivery for the
treatment of IC/PBS or OAB.2. IC/PBS
IC or PBS is a chronic disease characterized by suprapubic/
bladder discomfort accompanied by urinary frequency, urgency, or
nocturia, in the absence of infection or other pathological condi-
tions.7,8 This debilitating condition results in poor quality of life
with sleep dysfunction, sexual dysfunction, depression, anxiety,
and stress.9 IC/PBS is not a rare condition, and it occurs more
frequently in women than men. Recent studies have revealed that
between 2.7% and 6.5% women in the United States have symptoms
of IC/PBS.10
It was proposed that a dysfunctional epithelium allows the
transepithelial migration of toxic solutes, such as potassium, which
can depolarize subepithelial afferent nerves and provoke sensoryan LLC. Open access under CC BY-NC-ND license.
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dysfunction of the superﬁcial layer of the extracellular matrix the
glycosaminoglycan (GAG) layer, and downregulation of tight junc-
tional proteins were demonstrated to be related to IC.6,7,11 All of
these potential etiologies involves neurogenic inﬂammation, pri-
mary afferent nerve activation, and central nervous system sensi-
tization, all of which interact to perpetuate pain, frequency, and
urgency. Pain-sensing C ﬁbers are located within the uroepithelium
and submucosa of the bladder and can be activated by either a GAG
layer deﬁciency or release of histamine via mast cells or release of
sensory neurotransmitters from urothelium cells. Multimodal
treatment based on different mechanisms of action can improve
the therapeutic outcomes.7,9
3. OAB
OAB is deﬁned by the International Continence Society (ICS) as a
symptom complex suggestive of urinary urgency, with or without
urgency incontinence, usually with frequency and nocturia.12 It has
been estimated that the global prevalence of OAB was 10.7% in
2008, and this ﬁgure is expected to increase to 20.1% in 2018.13
There are three main factors to explain the pathophysiological
basis for OAB: neurogenic, myogenic, and urotheliogenic.14 The
neurogenic factor is based on observations that altered central
inhibitory pathways in the brain and spinal cord or sensitization of
peripheral afferent terminals in the bladder inappropriately trig-
gering the voiding reﬂex, increasing the efferent drive, and
inducing bladder overactivity.15 The myogenic factor states that
myocytes from the urinary bladder of patients have increased
spontaneous activity that allows excitation to widely propagate
through the bladder wall.12 It might be due to periodic ischemia of
the bladder and partial denervation of the detrusor, which conse-
quently augments the response of the detrusor to stimulation. The
urotheliogenic factor is based on evidence that the urothelium has
the character of neuron-like activity and is capable of detecting
thermal, mechanical, and chemical stimuli. Transmitters released
from the urothelium may alter the excitability of afferent nerves
and affect detrusor muscle contractility.16 In OAB, the release of
acetylcholine from the urothelium during the storage phase of
micturition can activate muscarinic receptors in the urothelium,
and trigger the release of urothelial ATP and nitric oxide, leading to
activation of the afferent pathway. Thus, antimuscarinics block
urothelial muscarinic receptors and indirectly act to reduce afferent
nerve activation and therefore decrease OAB symptoms.
4. Why use intravesical therapy for IC/PBS and OAB?
Most of the therapeutic agents for functional bladder disorders
are administered through the per oral route in large doses, without
signiﬁcant side effects but which often fail to have a sufﬁcient effect
at the disease site. With intravesical therapy, the doctor puts a
liquid drug directly into the bladder (through a catheter) rather
than giving it orally. The advantages of intravesical treatment
include: (1) delivery of high drug concentrations into the bladder,
(2) a lower incidence of systemic side effects, (3) direct repair of
bladder urothelial deﬁcits, and (4) modulation of aberrant uro-
thelial sensing or neurotransmission. The anatomy of the urinary
bladder connecting by urethra allows easy access andmanipulation
with a catheter and improves the exposure of the affected bladder
lining to the agent.17
5. Limitations of intravesical therapy
It is not uncommon for patientswith functional bladderdisorders
to be unable to hold a drug in the bladder for enough time. Thisgreatly reduces the residence timeof the drug in thebladder, thereby
reducing the therapeutic effects. A further shortcoming of intra-
vesical therapy is the progressive dilution of the instilled drug solu-
tion owing to theﬁlling upof urine in thebladder. Therefore, patients
receiving intravesical therapy are advised to empty their bladder
prior to drug instillation, anddecrease the rate of urineproductionby
regulating ﬂuid intake before and after drug administration.
6. Impermeable urothelium
The structure of the bladder wall contains the urothelium,
detrusor muscle, and adventitia from the luminal to the outer
surface. The urothelium serves as a bladder permeability barrier
and prevents urine and waste solute from penetrating into the
submucosal layer.18 The urothelium is composed of three different
cells: basal cells, intermediate cells, and umbrella cells, inwhich the
barrier function is established by the arrangement of uroplakins
and tight junctional protein and further enhanced by a mucin layer
composed of GAG on the luminal side. The GAG layer is hydrophilic
and forms an aqueous layer on umbrella cells. The GAG layer has
been suggested to prevent urine substances from adhering to the
bladder lumen. The barrier structure of the urothelium restricts the
movement of drugs after intravesical administration and also re-
stricts the action of the active drug fraction in the urine. Hence,
many drugs fail to reach the bladder at desired therapeutic levels
and ultimately lack pharmacological effects.19
7. LPsdnano approaches for intravesical drug delivery
To overcome the limited permeability of the bladder wall, the
intravesical approach is able to modulate the release and absorp-
tion characteristics of instilled drugs through coupling them to
novel carriers such as LPs, and other nanoparticles (particles with
one of the dimensions in nanometers). LPs are lipid vesicles
composed of synthetic or natural phospholipid bilayers that self-
assemble enclosing an aqueous interior. They can incorporate
various sizes of drug molecules both hydrophilic and hydrophobic,
and show greater uptake into cells via endocytosis.4 LPs, nontoxic
nature of the lipids, improved the delivery of chemotherapeutic
agents by altering the pharmacokinetics and have beenwidely used
as drug carriers for a variety of chemotherapeutic agents.20
8. Empty LPs for IC/PBS in preclinical and clinical studies
The intravesical delivery of hyaluronic acid, heparin, and chon-
droitin sulfate restores the barrier function lost due to epithelial
dysfunction in IC/PBS. The same concept can be applied to LPs for
the treatment of IC/PBS. A possible mechanism of action of LPs is
the formation of a lipid ﬁlm on the urothelium that protects it from
penetration by irritants, stabilization of neuromembranes of
damaged nerves, and reduction of their hyperexcitability.
Fraser et al21 examined the effect of intravesically administered
LPs of L-a-phosphatidylcholine/cholesterol at 2:1 in a rat model of
hyperactive bladder induced by protamine sulfate followed by KCl
or acetic acid infusion to mimic the interstitial cystitis state. The
cystometrographic results showed that the bladder hyperactivity
was partially reversed by treatment with the LP formulation. Tyagi
et al22 evaluated the comparative efﬁcacy of LPs against intravesical
instillation of dimethyl sulfoxide and pentosan polysulfate (PPS) in
chemically induced bladder hyperactivity in rats by sequential
infusion of protamine sulfate and potassium chloride. Intravesical
LPs were effective in doubling the intercontractile interval
compared with PPS, whereas acute instillation dimethyl sulfoxide
failed to produce any protective effect in this animal model.22
Metabolic syndrome created by feeding of fructose to rats can
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et al23 reported that the cystometric bladder capacity of metabolic
syndrome rats can be further decreased by instillation of acidic ATP
solution, which provokes reﬂex micturition via afferent noise (C
ﬁber pathway) and results in DO. The addition of LPs to the ATP
solution partially reversed the ATP solution induced response. A
recent study showed that LPs carrying a trace amount of near-
infrared (NIR) lipophilic carbocyanine dye 1,10-dioctadecyl-
3,3,30,30-tetramethylindotricarbocyanine iodide ﬂuoresces on
exposure to NIR light.24 The LPs coating the bladder surface was
indicated by blue coating on the bladder luminal surface in NIR
light.24 The study proved that LPs form a protective ﬁlm coating on
the injured bladder lumen surface and assist in the repair of leaky
and inﬂamed uroepithelium.
Chuang et al5 published the ﬁrst information on the clinical
safety and efﬁcacy of LPs in an open-labeled prospective study of 24
IC/PBS patients. The effect of intravesical LPs (80 mg/40mL distilled
water) once weekly was compared to that of oral PPS sodium
(100 mg) three times daily for 4 weeks each. Comparable efﬁcacy
rates of signiﬁcant decreases in urinary frequency and nocturia
were observed in each treatment group. Statistically signiﬁcant
decreases in pain, urgency, and O'Leary-Sant symptom were
observed in the LP group with the effect being most profound on
urgency. None of the patients reported urinary incontinence,
retention, or infection due to LP instillation.
Peters et al25 reported the results of 14 individuals with symp-
tomatic IC/PBS treated with intravesical LPs once per week for
4 weeks in an open-level study. No treatment-related adverse
events were found over the course of the study. Urgency scale and
Interstitial Cystitis Symptoms Index (ICSI) and Interstitial Cystitis
Problem Index (ICPI) were signiﬁcantly decreased at 4 weeks and
8 weeks after treatment. Pain Visual Analog Scale scores signiﬁ-
cantly decreased at 4 weeks after treatment. However, no signiﬁ-
cant decrease in urinary frequency was found.
Lee et al26 assessed the safety and efﬁcacy of twice weekly
administration of LPs on ﬁve patients with IC/PBS symptoms. The
O'Leary-Sant symptom/problem score, O'Leary-Sant total score, and
pain score at the 4-week follow-up showed signiﬁcantly greater
improvement from baseline with biweekly instillation than once
per week instillation. The follow-up at 8 weeks had similar effects
for both treatment regimens. Tolerability of LPs remained un-
changed from once per week regimen to twice per week regimen.
In conclusion, intravesical instillation of LPs was found to be safe for
IC/PBS with potential improvement after one course of therapy for
up to 8 weeks. Intravesical LPs appear to be a promising new
treatment for IC/PBS. Conﬁrmatory LP studies for IC/PBS are
anticipated at the time of writing in the United States.
9. LP delivery of botulinum toxin
The use of botulinum neurotoxin A (BoNT-A) for the treatment
of neurogenic DO and idiopathic DO has recently been approved by
the Food and Drug Administration. BoNT-A acts by cleaving the
soluble N-ethylmaleimide-sensitive fusion attachment protein re-
ceptor (SNARE) protein, SNAP-25,27 and inhibiting the release of
various neurotransmitters at the presynaptic vesicle by binding to
the synaptic vesicle protein, SV2, during neurotransmitter exocy-
tosis. BoNT-A has been shown tomodulate pain and inhibit afferent
neurotransmission including substance P, glutamate, nerve growth
factor, calcitonin gene related peptide, and adenosine triphos-
phate.28 Given the function of chemical denervation, BoNT-A has
been successfully used to treat OAB, as well as IC/PBS through a
cystoscopically guided injection. However, the method of intra-
vesical injection has certain adverse events, such as urinary tract
infection, urinary retention, pain, and hematuria.BoNT-A is a neurotoxinwith a highmolecular weight of 150 kDA,
whichmakes it difﬁcult to access the submucosal nerveplexus in the
normal use of saline as a vehicle without direct injection to pass the
urothelium barrier. Pretreatment of the urotheliumwith protamine
sulfate to improve the permeability to BoNT-A was attempted in
rats.29,30 The cationic protamine sulfate interacts with the anionic
GAG layer, leading to a slight increase in the permeability of the
urothelium.31 Based on the LPs' carrier potential and characteristics
of adsorption and fusionwith cells, the transport of BoNT-A into the
urothelium via LPs was conﬁrmed by detection of its unique effect
on neurotransmitters and proteolysis of synaptosomal associated
protein SNAP-25 through Western blotting and immunohisto-
chemistry. The protection of BoNT-A entrapped inside LPs from
degradation by proteases and proteinases in the urine without
compromising efﬁcacy was demonstrated by attenuation of acetic
acid induced bladder irritation in rats.32
Therefore, instillation of liposomal mediated BoNT-A (Lipo-
BoNT) into the bladder is an exciting approach to achieving sus-
tained duration of chemical neuromodulation of afferent neuro-
transmission underlying OAB and IC/PBS. A previous study has
reafﬁrmed the potential of LPs as a promising vehicle for delivery of
BoNT-A to the bladder.32
Kuo et al6 reported 24 OAB patients assigned for Lipo-BoNT
(80 mg LPs and 200 U BoNT-A) intravesical instillation or normal
saline (N/S) in a double-blind, randomized, parallel controlled pilot
trial. The primary end point at 1 month revealed a signiﬁcant
improvement of urinary frequency per 3 days in the Lipo-BoNT
group [n ¼ 12; median, 6.50; interquartile range (IQR),
from18.3 to0.25; p ¼ 0.008] but not in the N/S group (n ¼ 12.0;
IQR, from7.75 to8.0; p¼ 0.792). Furthermore, urgency episodes
decreased signiﬁcantly in the Lipo-BoNT group (12.0; IQR,
from20.3 to2.75; p¼ 0.012) but not in the N/S group (1.0; IQR,
from 11.0 to 2.5; p ¼ 0.196). The report also showed the SV2A
and SNAP25 expression in urothelial cells and suburothelial tissues;
however, the protein expression had no signiﬁcant difference be-
tween responders and nonresponders at 3 months after treatment.
The hypothesis is that the SNAP-25 proteins may have recovered by
3 months after treatment.
In another two-center, double-blind, randomized, placebo-
controlled study by Chuang et al,33 OAB patients refractory to anti-
muscarinicswere assigned for intravesical instillationof Lipo-BoNTor
normal saline. The micturition events per 3 days signiﬁcantly
decreased after 4weeks in the Lipo-BoNTgroup (4.64 for Lipo-BoNT
vs. 0.19 for placebo, p ¼ 0.0252). Urinary urgency also statistically
decreased in the Lipo-BoNTgroup with respect to baseline but not in
placebo. Moreover, the urgency severity scores in the Lipo-BoNT
group decreased signiﬁcantly compared to placebo (p ¼ 0.0181).
They reported these beneﬁts of Lipo-BoNT instillation without an
increased risk of urinary retention or urinary tract infection.
10. LP delivery of tacrolimus
Tacrolimus (FK506) is a potent hydrophobic immunosuppressive
agent that acts on inhibition of interleukin-2-dependent T cell
activation and has a direct inhibitory effect on cell-mediated im-
munity.34 Local treatment with tacrolimus has been shown to be
beneﬁcial in an ointment or lotion formulation against inﬂamma-
tory skin conditions without systemic side effects. The formulation
of liposomal tacrolimus overcomes its poor aqueous solubility for
biocompatible instillations. Our previous study demonstrated that
liposomal tacrolimus signiﬁcantly inhibited cyclophosphamide-
induced inﬂammatory cystitis through modulating interleukin-2,
prostaglandin E2, and prostaglandin E receptor 4 function.35 LPs
can signiﬁcantly increase the solubility of tacrolimus and facilitate
its absorption by increased vesicular trafﬁc via endocytosis into the
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et al36 evaluated the pharmacokinetics of tacrolimus encapsulated
in LPs (Lipo-tacrolimus). They found that the area under the plasma
drug concentration-time curve (AUC) of Lipo-tacrolimus in serum at
0e24 hours was signiﬁcantly lower than that of tacrolimus instil-
lation or injection, and the maximum concentration of Lipo-
tacrolimus in serum and urine was at 1 hour and at 2 hours,
respectively. Urine AUC (0e24) after intravesical administrationwas
signiﬁcantly higher than in the intraperitoneal group (p < 0.05).
Single-dose pharmacokinetics revealed that bladder instillation of
LP encapsulated tacrolimus signiﬁcantly decreased the systemic
exposure to instilled tacrolimus. Taken together, these ﬁndings
might support the investigation of local tacrolimus in cases of in-
ﬂammatory bladder disorders refractory to conventional therapy.
11. Conclusion
Intravesical LPs have shown promising potential in preclinical
and clinical investigations discussed above. LPs may have thera-
peutic effects on IC/PBS patients, mainly because of their ability to
form a protective lipid ﬁlm on the urothelial surface. LPs can
enhance vesicular trafﬁcking in the urothelium and aid in
improving the delivery of cargo across the bladder permeability
barrier. Encapsulation of botulinum toxin and tacrolimus inside LPs
protected it from urinary degradation without compromising the
efﬁcacy. Intravesical LP drug delivery may be an exciting new
treatment for sustained local bladder delivery to treat OAB, IC/PBS,
and other inﬂammatory bladder disorders.
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